![](/wp-content/uploads/2023/08/Screenshot-2023-08-17-at-2.43.06-PM.png)
$599
Zealand Q2 ’23 Earnings; TheracosBio Partners with SmithRx for Brenzavvy Access
Two cardiometabolic-related news items have been observed: Zealand Pharma hosted its Q2 ’23 earnings call (press release; slides); and TheracosBio announced a collaboration with SmithRx to offer access to Brenzavvy (bexagliflozin; view press release). Below, FENIX provides highlights and insights into the respective news items.